VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Trinasolar, a global leader in smart PV and energy storage solutions, has been awarded the Bankability certificate for its Vertex n-type TOPCon bifacial PV modules by TÜV Rheinland, an independent ...

Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity was originally published by The Motley Fool ...

ROI is in the forecast – 49% say they expect to achieve ROI through better forecasting and decision-making, closely followed by a more cost effective and future proofed technology architecture and a ...

Vertex (VERX – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero from ...

DelveInsight's Respiratory Disease Testing Market Insights report provides the current and forecast market analysis, individual ...

In May 2024, GSK announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and ...

Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ETCompany ParticipantsJoe Crivelli - Vice President, ...

Its first approved product, Casgevy, was developed in collaboration with narrow-moat Vertex Pharmaceuticals to treat transfusion ... our typical 9% cost of equity for other biotechs under our coverage ...

Q3 2024 Earnings Call Transcript November 4, 2024 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.38, expectations were $4.14. Operator: Good day. And welcome to ...